MAPT and Alzheimer disease: In recent AD criteria [7, 8], the levels of CSF Aβ1-42, tau, p-tau181, as well as PET imaging results have been established as core AD biomarkers to define the progressive stages in AD continuum, including preclinical AD, mild cognitive decline (MCI) due to AD, and dementia due to AD.